Duquesne Family Office’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-906,767
| Closed | -$8.94M | – | 86 |
|
|
2023
Q4 | $8.94M | Hold |
906,767
| – | – | 0.27% | 41 |
|
|
2023
Q3 | $6.94M | Sell |
906,767
-479,183
| -35% | -$3.67M | 0.25% | 32 |
|
|
2023
Q2 | $10.4M | Hold |
1,385,950
| – | – | 0.36% | 37 |
|
|
2023
Q1 | $9.26M | Hold |
1,385,950
| – | – | 0.4% | 31 |
|
|
2022
Q4 | $10.7M | Hold |
1,385,950
| – | – | 0.53% | 32 |
|
|
2022
Q3 | $14.7M | Buy |
1,385,950
+1,112,300
| +406% | +$11.8M | 0.84% | 29 |
|
|
2022
Q2 | $2.23M | Hold |
273,650
| – | – | 0.16% | 32 |
|
|
2022
Q1 | $1.96M | Buy |
273,650
+13,709
| +5% | +$98.1K | 0.09% | 45 |
|
|
2021
Q4 | $4.45M | Hold |
259,941
| – | – | 0.16% | 40 |
|
|
2021
Q3 | $5.98M | Buy |
+259,941
| New | +$5.98M | 0.19% | 39 |
|